Granzyme B in injury, inflammation, and repair

Trends in Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 732-741

  Hiebert, Paul R ^a   Granville, David J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Aging; Extracellular matrix; Granzyme B; Inflammation; Skin; Wound healing

Indexed keywords

GRANZYME B;

AGING; CHRONIC INFLAMMATION; CHRONIC WOUND; CUTANEOUS PARAMETERS; HUMAN; NONHUMAN; REVIEW; SKIN FRAGILITY; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EXTRACELLULAR MATRIX PROTEINS; GRANZYMES; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; SKIN AGING; SUBSTRATE SPECIFICITY; WOUND HEALING;

EID: 84870255907     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.09.009     Document Type: Review

References (98)

1. Xue M., et al. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin. Ther. Targets 2006, 10:143-155.
2. Gill S.E., Parks W.C. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 2008, 40:1334-1347.
3. Yager D.R., Nwomeh B.C. The proteolytic environment of chronic wounds. Wound Repair Regen. 1999, 7:433-441.
4. Boivin W.A., et al. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab. Invest. 2009, 89:1195-1220.
5. Hendel A., et al. Granzymes in age-related cardiovascular and pulmonary diseases. Cell Death Differ. 2010, 17:596-606.
6. Hatcher V.B., et al. A cytotoxic proteinase isolated from human lymphocytes. J. Immunol. 1978, 120:665-670.
7. Simon M.M., et al. Purification and characterization of a T cell specific serine proteinase (TSP-1) from cloned cytolytic T lymphocytes. EMBO J. 1986, 5:3267-3274.
8. Bleackley R.C., et al. Isolation of two cDNA sequences which encode cytotoxic cell proteases. FEBS Lett. 1988, 234:153-159.
9. Pasternack M.S., Eisen H.N. A novel serine esterase expressed by cytotoxic T lymphocytes. Nature 1985, 314:743-745.
10. Masson D., et al. Granules of cytolytic T-lymphocytes contain two serine esterases. EMBO J. 1986, 5:1595-1600.
11. Brunet J.F., et al. The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14. Nature 1986, 322:268-271.
12. Young J.D., et al. Isolation and characterization of a serine esterase from cytolytic T cell granules. Cell 1986, 47:183-194.
13. Barry M., Bleackley R.C. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2002, 2:401-409.
14. Smyth M.J., Trapani J.A. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol. Today 1995, 16:202-206.
15. Kagi D., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.
16. Kagi D., et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994, 265:528-530.
17. Henkart P.A. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1994, 1:343-346.
18. Cooper D.M., et al. Granzyme K activates protease-activated receptor-1. PLoS ONE 2011, 6:e21484.
19. Joeckel L.T., et al. Mouse granzyme K has pro-inflammatory potential. Cell Death Differ. 2011, 18:1112-1119.
20. Metkar S.S., et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 2008, 29:720-733.
21. Froelich C.J., et al. Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol. 2009, 30:117-123.
22. Anthony D.A., et al. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J. Immunol. 2010, 185:1794-1803.
23. Buzza M.S., et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J. Biol. Chem. 2005, 280:23549-23558.
24. Choy J.C., et al. Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2245-2250.
25. Hiebert P.R., et al. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp. Gerontol. 2011, 46:489-499.
26. Froelich C.J., et al. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J. Immunol. 1993, 151:7161-7171.
27. Boivin W.A., et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1. PLoS ONE 2012, 7:e33163.
28. Afonina I.S., et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell 2011, 44:265-278.
29. Omoto Y., et al. Granzyme B is a novel interleukin-18 converting enzyme. J. Dermatol. Sci. 2010, 59:129-135.
30. Chamberlain C.M., et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am. J. Pathol. 2010, 176:1038-1049.
31. Ang L.S., et al. Serpina3n attenuates granzyme B-mediated decorin cleavage and rupture in a murine model of aortic aneurysm. Cell Death Dis. 2011, 2:e209.
32. Hagn M., et al. Activated mouse B cells lack expression of granzyme B. J. Immunol. 2012, 188:3886-3892.
33. Hagn M., et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J. Immunol. 2009, 183:1838-1845.
34. Pham C.T., et al. Long-range disruption of gene expression by a selectable marker cassette. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13090-13095.
35. Kaiserman D., et al. The major human and mouse granzymes are structurally and functionally divergent. J. Cell Biol. 2006, 175:619-630.
36. Poe M., et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J. Biol. Chem. 1991, 266:98-103.
37. Kurschus F.C., et al. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett. 2004, 562:87-92.
38. Tremblay G.M., et al. Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors. J. Immunol. 2000, 165:3966-3969.
39. Prakash M.D., et al. Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytes in the absence of target cell engagement. Immunol. Cell Biol. 2009, 87:249-254.
40. McElhaney J.E., et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012, 30:2060-2067.
41. Nishiyama T., et al. The importance of laminin 5 in the dermal-epidermal basement membrane. J. Dermatol. Sci. 2000, 24(Suppl. 1):S51-S59.
42. Posadas S.J., et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J. Allergy Clin. Immunol. 2002, 109:155-161.
43. Danielson K.G., et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997, 136:729-743.
44. Carrino D.A., et al. Age-related changes in the proteoglycans of human skin. Specific cleavage of decorin to yield a major catabolic fragment in adult skin. J. Biol. Chem. 2003, 278:17566-17572.
45. Hernandez-Pigeon H., et al. UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodeling. J. Biol. Chem. 2007, 282:8157-8164.
46. Hernandez-Pigeon H., et al. Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation. Implication of granzyme B and perforin. J. Biol. Chem. 2006, 281:13525-13532.
47. Pardo J., et al. Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ. 2007, 14:1768-1779.
48. Strik M.C., et al. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol. Immunol. 2007, 44:3462-3472.
49. Tschopp C.M., et al. Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma. Blood 2006, 108:2290-2299.
50. Kramer M.D., Simon M.M. Are proteinases functional molecules of T lymphocytes?. Immunol. Today 1987, 8:140-142.
51. Sower L.E., et al. Extracellular activities of human granzymes. I. Granzyme A induces IL6 and IL8 production in fibroblast and epithelial cell lines. Cell. Immunol. 1996, 171:159-163.
52. Irmler M., et al. Granzyme A is an interleukin 1β-converting enzyme. J. Exp. Med. 1995, 181:1917-1922.
53. Vignali D.A., et al. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
54. Wang T., et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS ONE 2012, 7:e43950.
55. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
56. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 2005, 174:1783-1786.
57. Norris D.A., et al. Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J. Immunol. 1982, 129:1612-1618.
58. Clark R.A., et al. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J. Biol. Chem. 1988, 263:12115-12123.
59. Postlethwaite A.E., et al. Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J. Exp. Med. 1981, 153:494-499.
60. Bowersox J.C., Sorgente N. Chemotaxis of aortic endothelial cells in response to fibronectin. Cancer Res. 1982, 42:2547-2551.
61. Birdsall H.H., et al. Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes. J. Immunol. 2004, 173:2746-2754.
62. Okamura Y., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 2001, 276:10229-10233.
63. Schaefer L., et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:2223-2233.
64. Merline R., et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
65. Sharron M., et al. Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. PLoS ONE 2012, 7:e41549.
66. Buzza M.S., et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J. Biol. Chem. 2008, 283:22498-22504.
67. Mulligan-Kehoe M.J., et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007, 56:3448-3458.
68. Barone E.J., et al. Interleukin-1α and collagenase activity are elevated in chronic wounds. Plast. Reconstr. Surg. 1998, 102:1023-1027. discussion 1028-1029.
69. Yagisawa M., et al. Stimulation and priming of human neutrophils by IL-1α and IL-1β: complete inhibition by IL-1 receptor antagonist and no interaction with other cytokines. Exp. Hematol. 1995, 23:603-608.
70. Clark R.A. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J. Invest. Dermatol. 1990, 94:128S-134S.
71. Grinnell F., et al. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J. Invest. Dermatol. 1992, 98:410-416.
72. Wysocki A.B., Grinnell F. Fibronectin profiles in normal and chronic wound fluid. Lab. Invest. 1990, 63:825-831.
73. Stanley C.M., et al. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J. Periodontol. 2008, 79:861-875.
74. Ongenae K.C., et al. Level of fibronectin mRNA is markedly increased in human chronic wounds. Dermatol. Surg. 2000, 26:447-451.
75. Herrick S.E., et al. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J. Invest. Dermatol. 1996, 106:187-193.
76. Upton Z., et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J. Invest. Dermatol. 2008, 128:1535-1544.
77. Preissner K.T., Reuning U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin. Thromb. Hemost. 2011, 37:408-424.
78. To W.S., Midwood K.S. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 2011, 4:21.
79. Usui M.L., et al. Keratinocyte migration, proliferation, and differentiation in chronic ulcers from patients with diabetes and normal wounds. J. Histochem. Cytochem. 2008, 56:687-696.
80. Jarvelainen H., et al. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 2006, 14:443-452.
81. Mietz H., et al. Decorin and suramin inhibit ocular fibroblast collagen production. Graefes Arch. Clin. Exp. Ophthalmol. 1997, 235:399-403.
82. Shimizukawa M., et al. Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284:L526-L532.
83. Kolb M., et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 2001, 163:770-777.
84. Kolb M., et al. Proteoglycans decorin and biglycan differentially modulate TGF-β-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L1327-L1334.
85. Carrino D.A., et al. Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. Biochem. J. 2012, 443:361-368.
86. Honardoust D., et al. Reduced decorin, fibromodulin, and transforming growth factor-β3 in deep dermis leads to hypertrophic scarring. J. Burn Care Res. 2012, 33:218-227.
87. Westergren-Thorsson G., et al. Lung fibroblast clones from normal and fibrotic subjects differ in hyaluronan and decorin production and rate of proliferation. Int. J. Biochem. Cell Biol. 2004, 36:1573-1584.
88. Wu J., et al. Deficiency of the decorin core protein in the variant form of Ehlers-Danlos syndrome with chronic skin ulcer. J. Dermatol. Sci. 2001, 27:95-103.
89. Bernstein E.F., et al. Differential expression of the versican and decorin genes in photoaged and sun-protected skin. Comparison by immunohistochemical and northern analyses. Lab. Invest. 1995, 72:662-669.
90. Zhang Z., et al. Recombinant human decorin inhibits TGF-β1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 2009, 35:527-537.
91. Mukhopadhyay A., et al. Syndecan-2 and decorin: proteoglycans with a difference - implications in keloid pathogenesis. J. Trauma 2010, 68:999-1008.
92. Aso Y., et al. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diabet. Med. 2002, 19:19-26.
93. Murakami M., et al. A case of von Willebrand disease discovered during treatment of a sacral pressure ulcer. J. Nippon Med. Sch. 2010, 77:325-327.
94. Herouy Y., et al. Plasminogen activation in venous leg ulcers. Br. J. Dermatol. 2000, 143:930-936.
95. Browse N.L., Burnand K.G. The cause of venous ulceration. Lancet 1982, 2:243-245.
96. Amadeu T.P., et al. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen. 2004, 12:169-174.
97. Ikeda M., et al. Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. Biochem. Biophys. Res. Commun. 2009, 390:1221-1228.
98. Ashcroft G.S., et al. Age-related changes in the temporal and spatial distributions of fibrillin and elastin mRNAs and proteins in acute cutaneous wounds of healthy humans. J. Pathol. 1997, 183:80-89.